sglt2 inhibitors vs glp-1 SGLT-2 and Agonists: First-Line Therapy for Diabetes With Established Cardiovascular Disease sglt2inhibitors #glp1receptoragonist #sglt2i #glp1 #nsmra

Others mean a sour taste in the mouth, a feeling of food coming back up, or discomfort that feels more like bloating or fullness

NICE guidelines (NG28) support the use of GLP-1 receptor agonists for type 2 diabetes when glycaemic targets are not achieved with other therapies, and for weight management in specific circumstances (TA875 for Wegovy, TA664 for Saxenda)

This level of weight loss is associated with a wide range of benefits, such as improved mobility, enhanced mental well-being, and reduced risks of chronic diseases associated with obesity

INSL5 activates multiple signalling pathways and regulates GLP-1 secretion in NCI-H716 cells